A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus
Objective To evaluate the clinical utility of the multianalyte assay panel (MAP), commercially known as AVISE Lupus test (Exagen Inc.), in patients suspected of SLE.Methods A systematic review of medical records of ANA-positive patients with a positive (>0.1) or negative (<−0.1) MAP sc...
Main Authors: | John Conklin, Vinicius Domingues, Roberta Vezza Alexander, Arthur Weinstein, Mansoor Ahmed, Daniel Scott Rey, Jazibeh Qureshi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2021-07-01
|
Series: | Lupus Science and Medicine |
Online Access: | https://lupus.bmj.com/content/8/1/e000528.full |
Similar Items
-
A Multianalyte Assay Panel With Cell‐Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology–Classified Lupus
by: Rosalind Ramsey‐Goldman, et al.
Published: (2021-02-01) -
Can Cell Bound Complement Activation Products Predict Inherited Complement Deficiency in Systemic Lupus Erythematosus?
by: Naveen Raj, et al.
Published: (2016-01-01) -
Cell-bound complement activation products associate with lupus severity in SLE
by: Richard A Furie, et al.
Published: (2020-12-01) -
Noninvasive multianalyte diagnostic assay for monitoring bladder cancer recurrence
by: Shore ND, et al.
Published: (2012-10-01) -
Complement deficiency in pediatric-onset systemic lupus erythematosus
by: Parisa Afzali, et al.
Published: (2018-04-01)